Skip to main content

Table 5 Results from Year 5 sample, mortality follow-up of up to 10 years

From: Pre- and post-bronchodilator lung function as predictors of mortality in the Lung Health Study

  Hazards Ratio 95% Confidence Interval
Sex   
   Male 1.36 (1.12, 1.64)
   Female 1.00  
Age 1.09 (1.07, 1.10)
Body Mass Index 1.01 (0.98, 1.03)
Education   
   < 12 Years 1.24 (0.96, 1.59)
   12 Years 1.10 (0.90, 1.34)
   > 12 Years 1.00  
Race   
   White 1.00  
   Black 1.77 (1.22, 2.56)
Smoking Status   
   Former Smoker 0.63 (0.50, 0.80)
   Intermittent Smoker 0.85 (0.64, 1.13)
   Current Smoker 1.00  
Randomization Group   
   Intervention, Ipratroprium 0.86 (0.69, 1.07)
   Intervention, Placebo 0.91 (0.74, 1.13)
   Control 1.00  
Stage (Pre-bronchodilator)*   
   Stage 3 or 4 2.68 (1.51, 4.75)
   Stage 2 1.60 (0.94, 2.69)
   Stage 1 1.12 (0.63, 1.98)
   Restricted 2.25 (1.04, 4.86)
   Normal 1.00  
Stage (Post-bronchodilator)*   
   Stage 3 or 4 2.46 (1.63, 3.73)
   Stage 2 1.11 (0.82, 1.51)
   Stage 1 0.74 (0.52, 1.06)
   Restricted 1.36 (0.74, 2.47)
   Normal 1.00  
  1. *Modified chronic obstructive pulmonary disease stage, as defined in methods